

Table - Drugs in Development for the Treatment of CHB

Direct Acting Antivirals: Targets the virus and interferes in the HBV replication process		
Silencing RNA's (siRNAs): Interferes and destroys viral RNA		
Drug/Compound	Mechanism of Action	Development Phase
VIR-2218	RNAi gene silencer	Phase II
RG6004	RNAi gene silencer	Phase I/II
ARO-HBV	RNAi gene silencer	Phase I/II
AB-729	RNAi gene silencer	Phase I
DCR-HBVS	RNAi gene silencer	Phase I
BB-103	RNAi gene silencer	Preclinical
Lunar-HBV	RNAi gene silencer	Preclinical
Entry Inhibitors: Interferes with HBV getting into liver cells		
Bulevirtide (Myrcludex B)	Entry inhibitor	Phase IIb
Capsid Inhibitors: Interferes with the viral DNA protein shield		
Morphothiadin	Capsid inhibitor	Phase II
JNJ 56136379	Capsid inhibitor	Phase II
ABI-H0731	Capsid inhibitor	Phase II
ABI-H2158	Capsid inhibitor	Phase I
RG7907	Capsid inhibitor	Phase I
QL-007	Capsid inhibitor	Phase I
EDP-514	Capsid inhibitor	Phase I
GLP-26	Capsid inhibitor	Preclinical
ABI-H3733	Capsid inhibitor	Preclinical
CB-HBV-001	Capsid inhibitor	Preclinical
HBsAg Inhibitors: Interferes with production of HBV surface antigen (sAg)		
REP 2139	sAg inhibitor	Phase II
REP 2165	sAg inhibitor	Phase II
Antisense Molecules: Binds to the viral mRNA to prevent it from turning into viral protein		
IONIS-HBVRx	Viral protein inhibitor	Phase II
IONIS-HBVLRx	Viral protein inhibitor	Phase II
Indirect Acting Antivirals: Targets the human immune system to attack the HBV virus		
Therapeutic Vaccines: Vaccine technology used to stimulate the immune system as a treatment		
AIC 649	Therapeutic vaccine	Phase I
INO-1800	Therapeutic vaccine	Phase I
HB-110	Therapeutic vaccine	Phase I
TG1050	Therapeutic vaccine	Phase I
HepTcell	Therapeutic vaccine	Phase I
JNJ 64300535	Therapeutic vaccine	Preclinical
HBV	Therapeutic vaccine	Preclinical
VBI-2601	Therapeutic vaccine	Preclinical
Chimigen HBV	Therapeutic vaccine	Preclinical
CARG-201	Therapeutic vaccine	Preclinical
Innate Immune Defense Pathway: Compounds that activate the innate immune system		
Inarigivir	RIG -1 and NOD2 agonist	Phase II
GS9688	TLR-8 agonist	Phase I

RG7854	TLR-7 agonist	Phase I
Host Acting Pathway: Compounds that target cell functions needed by the hepatitis B virus		
APG-1387	Apoptosis Inducer	Phase I
CRV 431 (CPI 431-32)	Ciclofillin inhibitor	Preclinical
AB-452	RNA destabilizer	Preclinical
Gene Editing		
EBT106	CRISPR/Cas 9	Preclinical
HBV	ARCUS platform	Preclinical
Other		
GC1102	sAg monoclonal antibody	Phase II
EYP001	FXR agonist	Phase I
RG6084	Host targeting antisense (LNA)	Phase I
RG6217	Host targeting antisense (LNA)	Phase I
LTCR-H2-1	T Cell immunotherapy	Preclinical
HBV	MicroRNA	Preclinical